Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod dose-ranging study in active dermatomyositis
2013-001799-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of siponimod in dermatomyositis (DM) (5 arms), sponsored by Novartis. Primary endpoints: Manual Muscle Testing - 24 muscles (MMT-24) and Dose-response of MMT-24. Started Aug 2013; status: completed.
02
Drugs
siponimod
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2013-001799-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001799-39.